Australian TGA gives orphan status to angioedema drug
This article was originally published in Scrip
Executive Summary
Australia's Therapeutic Goods Administration ( TGA) has awarded Shire's bradykinin B2 receptor antagonist Firazyr (icatibant) orphan drug status, for the treatment of acute attacks of hereditary angioedema. Firazyr is available in 30mg/3mL pre-filled syringes. It received designated status on February 12th.